CAMBRIDGE, Mass., Sept. 2,
2022 /PRNewswire/ -- Akebia Therapeutics, Inc.
(Nasdaq: AKBA), a biopharmaceutical company with the purpose to
better the lives of people impacted by kidney disease, granted six
newly-hired employees options to purchase an aggregate of 27,000
shares of Akebia's common stock on August
31, 2022, as inducements material to each such employee
entering into employment with Akebia. The options were granted in
accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $0.36 per share, which is equal to the closing
price of Akebia's common stock on the grant date. Each stock option
vests over four years, with 25% of the shares vesting on the first
anniversary of the grant date and the remaining 75% of shares
vesting quarterly thereafter, in each case, subject to the new
employee's continued service with Akebia. Each stock option has a
10-year term and is subject to the terms and conditions of Akebia's
inducement award program and a stock option agreement covering the
grant.
About Akebia
Therapeutics
Akebia Therapeutics, Inc. is a fully integrated
biopharmaceutical company with the purpose to better the lives of
people impacted by kidney disease. Akebia was founded in 2007 and
is headquartered in Cambridge,
Massachusetts. For more information, please visit our
website at www.akebia.com, which does not form a part of this
release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301617157.html
SOURCE Akebia Therapeutics